DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ocaratuzumab
Ocaratuzumab
Project Presentation
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Combination Therapies with Anti-Cd38 Antibodies Kombinationstherapien Mit Anti-Cd38-Antikörpern Polythérapies Avec Des Anticorps Anti-Cd38
New Biological Therapies: Introduction to the Basis of the Risk of Infection
Biomolecules
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Tanibirumab (CUI C3490677) Add to Cart
The Two Tontti Tudiul Lui Hi Ha Unit
Ep 3178848 A1
Systematic Review of Therapy Used in Relapsed Or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Engineering Bispecific Antibodies for Targeted Delivery of Cytotoxin- Loaded Nanoparticles to Tumour Cells
(INN) for Biological and Biotechnological Substances
Treatment of Non-Hodgkin Lymphoma
New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies
Zydelig-H-C-003843-Ii-0011-Epar-Assessment-Report-Variation En.Pdf
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
Monoclonal Antibody (Mab)-Based Biotherapy Options for B-Lineage
Recent Biotherapies and Infections
Top View
(INN) for Biological and Biotechnological Substances
Invivogen Insight Newsletter
Development of Novel Anti-Cd20 Monoclonal Antibodies And
Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies Karl R
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Chapter 2 FIGURE 1 Timeline of Clinical Development and Approval of CD20 Targeting Antibodies
Ibrutinib- Obinutuzumab Chlorambucil
1 1 RISK FACTORS an Investment in Genmab's Shares, Including Any New Shares, Involves a High Degree of Risk. in Addition to Th
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens
Fc-Engineering for Modulated Effector Functions—Improving Antibodies
Fc-Engineered Antibodies with Enhanced Fc-Effector Function For
1494 More Zr 89 Monocolonal Antibody And
Making Rituximab Directly Cytotoxic for Substantial Improvement in Therapeutic Efficacy
International Nonproprietary Names for Pharmaceutical Substances (INN)
Characterization of Rituximab-Induced B Cell Depletion and Infusion Reactions in a Human Blood Loop System
Updates in the Treatment of Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma Kirollos S
Anti-Alphavbeta3 Monoclonal Antibody EMD 525797 (CUI C2830088) Add to Cart
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
(INN) for Biological and Biotechnological Substances
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
AME-133V in Follicular Lymphoma